Clinical Trials
16 trialsNCT05874414 2026-05-14
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Genfit
Phase 1/2 Recruiting
NCT05358249 2026-04-14
KontRASt-03
Novartis
Phase 1/2 Active not recruiting
NCT07468071 2026-04-02
KontRASt-R
Novartis
Phase 1/2 Not yet recruiting
NCT05907304 2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1 Active not recruiting
NCT04294160 2025-12-24
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Novartis
Phase 1 Terminated
NCT03377361 2025-12-03
CheckMate 9N9
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05275374 2025-04-10
ENHANCE
Xynomic Pharmaceuticals, Inc.
Phase 1/2 Not yet recruiting
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Phase 1 Completed
NCT01750918 2021-10-29
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Novartis
Phase 1/2 Completed
NCT02703571 2020-12-21
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
Novartis
Phase 1 Terminated
NCT01155453 2020-12-09
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients
Novartis
Phase 1 Completed
NCT01324258 2017-11-13
Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00955773 2017-11-09
Cancer
GlaxoSmithKline
Phase 1 Completed
NCT02538627 2017-09-05
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
Merrimack Pharmaceuticals
Phase 1 Terminated
NCT01943864 2017-05-31
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
GlaxoSmithKline
Phase 2 Completed